To understand the mechanisms leading to trastuzumab resistance in HER2-overexpressing breast tumors we created trastuzumab insensitive cell lines (SKBR3/100-8 and BT474/100-2). The cell lines maintain HER2 receptor overexpression, and show increase in EGFR. Upon trastuzumab treatment, SKBR3/100-8 and BT474/100-2 cell lines displayed increased growth rate and Wnt3 transfectants, SKBR3/Wnt3-7 and SKBR3/Wnt3-9, showed a significant decrease in Ecadherin and increase in N-cadherin, Twist and SLUG. The cells were less sensitive to trastuzumab compared to parental SKBR3 and vector transfected cells. In summary, our data suggests that Wnt3 overexpression activates Wnt/β-catenin signaling pathway that leads to transactivation of EGFR and promotes EMT-like transition. This could be an important mechanism leading to trastuzumab resistance in HER2 overexpressing breast cancer cells.
Introduction
Trastuzumab treatment has improved the overall survival rate of patients with HER2-overexpressing breast cancer. However, some patients with HER2-overexpressing breast cancer do not respond to trastuzumab therapy, as a single agent or in combination with chemotherapy, and the mechanisms underlying the resistance phenotype are not well understood. Some studies have suggested increase in HER2 receptor homo-and hetero-dimerization with other receptors of the ErbB family, such as epidermal growth factor receptor (EGFR), HER3, and HER4 (1, 2).
These interactions activate intracellular signaling via the mitogen-activated protein kinase (MAPK), or phosphatidylinositol 3-kinase (PI3K) pathways (3, 4) . We have previously shown that activation of PI3K/Akt pathway inhibited the transcription factor FOXO1A, resulting in nuclear export of p27 kip1 and reduced the inhibitory properties of trastuzumab (5) . Breast cancer patients with HER2-overexpressing tumors have increased active Akt (pAkt) in their tumors (6) .
The activation of PI3K/Akt and loss of PTEN may also result in accumulation of β-catenin, which suggests a crosstalk between the PI3K and Wnt signaling pathways (7) (8) (9) (10) (11) .
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The human breast cancer cell lines SKBR3 (ATCC: HTB-30) and BT474 (ATCC: were obtained from the American Type Culture Collection. Unless otherwise stated, monolayer cultures of SKBR3 and BT474 cells were maintained in DMEM/F12 medium with 10% fetal bovine serum. The cell lines overexpressed the HER2/c-erb-2 (HER2) gene product. The trastuzumab resistant clones, SKBR3/100-8 and BT474/100-2 were generated from SKBR3 and BT474 cells respectively. In order to select trastuzumab resistant clones, SKBR3 and BT474 cells were plated in 24 well plates at low density and maintained in growth medium containing 10μg/ml, 50μg/ml and 100μg/ml of trastuzumab. The SKBR3/100-8 and BT474/100-2 clones were maintained in growth medium containing 100μg/ml of trastuzumab for over 2 years and 1 year, respectively. Both SKBR3/100-8 and BT474/100-2 were repeatedly confirmed as insensitive to trastuzumab. The SKBR3/Wnt3-7 and SKBR3/Wnt3-9 were generated by stable transfection of full length Wnt genes) into SKBR3 cells, as well as clonal selection.
Microarray analysis
Total RNA was isolated from SKBR3 and SKBR3/100-8 cultured cells by using RNeasy micro kit (#74004, QIAGEN). The quality of RNA was determined by separation of the RNA via capillary electrophoresis using the Agilent 2100 Bioanalyzer. Whole Human Genome 4X44K (Cat#: G4112F, Agilent) expression array was used to compare the gene profiles between SKBR3 and SKBR3/100-8. Microarray slides were read using Agilent Scanner. Agilent Feature Extraction software version 9.13 was used to calculate the gene expression values. Differences of p<0.01 and ≥2-fold expression were considered as significant.
The Wnt/β-catenin pathway regulated gene profiles in the cell lines were examined using Human Wnt/β-catenin Regulated cDNA plate array (Cat# AP-0171, Signosis; Sunnyvale, CA) according to manufacturer's instructions. Table 1 ). /mL) were placed in the upper wells and fibroblastconditioned medium was filled in the lower wells. The cells were cultured for 24 hrs and then fixed by 0.5 ml of 0.5% Glutaraldehyde in 1xPBS and stained by 0.5 ml of 0.5% Toluidine Blue.
Overexpressing Wnt3 gene
The numbers of invaded cells were counted with 20X objective of microscope from 3 files per membrane and then normalized with total numbers of cells. Each experiment was performed twice and each condition was duplicated at each time.
Chromatin immunoprecipitation-Real-time PCR assay (ChIP-qPCR)
The chromatin-protein complex was prepared from SKBR3 and SKBR3/100-8 cells by immunoprecipitation of the chromatin with β-catenin antibody using Magna-ChIP assay kit (Cat# 17-10085, Millipore) following the manufacture's instruction and then qPCR was performed. The primer sequences were designed to cover the LEF/TCF binding region of the promoter of EGFR (711-727): Lt: 5'-GCCTGGTCCCTCCTCCTC-3' and Rt: 5'-GCTCTCCCGATCAATACTGG-3'. Fold enrichment in the β-catenin precipitated samples was calculated relative to the mock samples (precipitated with normal IgG). The data was also calculated as % input to ensure consistent results. were used to extract the nuclear and cytoplasmic protein following the manufacturer's instructions. Immunoblotting analysis was performed with antibodies specific to HER2, Ecadherin, β-catenin, and Histone from cell signaling, EGFR, Wnt3, MMP-7, VEGF, α-Tubulin and β-actin from Santa Cruz Biotechnology.
Immunoblotting analysis

Statistical analysis
The statistical significances of mean values among different cell lines were determined by oneway ANOVA first, then by Student t test, and the fold changes were analyzed by χ 2 test. P-value < 0.05 was considered statistically significant.
Results
Characterization of trastuzumab resistant cell lines, SKBR3/100-8 and BT474/100-2
Data from MTT assay showed that the growth of SKBR3 and BT474 parental cells was significantly inhibited by fresh treatment with 10μg/ml and 100μg/ml of trastuzumab, while the growth of SKBR3/100-8 and BT474/100-2 cells which were maintained in media containing trastuzumab 100μg/ml were not inhibited in 5 days ( Figure 1A Both SKBR3/100-8 and BT474/100-2 showed increased EGFR compared to parental cell lines ( Figure 1B right) . The HER2/HER3 dimerization was increased in SKBR3/100-8 (supplemental Figure 1 ), but no changes were found in BT474/100-2 (data not shown). Both SKBR3/100-8 and BT474/100-2 cells displayed significant enhanced invasive capacity ( Figure 1C ).
Compared to parental SKBR3 and BT474 cells, the SKBR3/100-8 and BT474/100-2 cells had decreased E-cadherin and increased mesenchymal markers, N-cadherin, SLUG, and Twist ( Figure 1D ). Vimentin expression increased in BT474/100-2 compared to BT474, but there was no difference between SKBR3/100-8 and SKBR3 cells ( Figure 1D ). Figure 3A) . The Wnt3 and Wnt6 were also significantly upregulated in BT474/100-2 compared to BT474 (supplemental Figure 3B ).
Activation of Wnt/β-catenin signaling pathway promotes EMT phenotype and transcriptionally regulates EGFR in trastuzumab resistant cell lines
To further verify the activation of the Wnt/β-catenin signaling pathway in trastuzumab resistant cells a human Wnt/β-catenin regulated cDNA plate array was used. The array consisted of 22 Wnt/β-catenin pathway regulated genes; most genes in the array were up-regulated in the resistant clones, SKBR3/100-8 and BT474/100-2 cells ( Figure 2B ). Twelve genes were upregulated >2 fold in SKBR3/100-8 compared to SKBR3, and eight genes were up-regulated ≥2 fold in BT474/100-2 compared to BT474. The β-catenin was up-regulated ~3 fold in both SKBR3/100-8 and BT474/100-2 clones. The c-Jun, c-Myc, Sox9 and survivin were also up- Figure 3A showed that protein level of Ecadherin was decreased and Twist was increased in both SKBR3/100-8 and BT474/100-2 cells.
Even though the mRNA level of Vimentin was similar between SKBR3 and SKBR3/100-8 ( Figure 1D ), however, we found increased protein level of Vimentin in SKBR3/100-8 compared to SKBR3. The SKBR3/100-8 cells also had increased N-cadherin protein expression ( Figure 3 ).
The protein level of N-cadherin was undetectable in BT474 and BT474/100-2 cells. These results confirmed the PCR data of decreased E-cadherin and increased EMT markers in the trastuzumab resistant cell lines, as shown in Figure 1D . The decrease in E-cadherin and increase in Ncadherin were generally seen across most of SKBR3/100-8 cells, compared to SKBR3 (supplemental Figure 5A and 5B). The results implied that activation of Wnt signaling might promote EMT or partial EMT-like transition in the trastuzumab resistant cells.
We further examined the localization of β-catenin protein expression in SKBR3 and SKBR3/100-8 cells. Data in Figure 3B showed that β-catenin was mainly present in the Conversely the Twist protein level was not changed in SKBR3/100-8 after knockdown of Wnt3 ( Figure 3E, right) . The E-cadherin protein expression was up-regulated in SKBR3/100-8 after Wnt3 knockdown which was consistent with its mRNA level.
Next, we examined if Wnt3 knockdown could sensitize cells in response to trastuzumab. The SKBR3/100-8 and BT474/100-2 cells were treated with siRNA-Wnt3 or negative control sequence (siRNA-A) for 48 hrs followed by fresh treatment with 20μg/ml to 200μg/ml of trastuzumab for 72hrs. The data in Figure 4A The down-regulation of Wnt3 by siRNA also resulted in decreased nuclear expression of β-catenin protein in SKBR3/100-8 cells and down-regulation of mRNA level of EGFR by 30% and 26% in SKBR3/100-8 and BT474/100-2, respectively ( Figure 4C ). In contrast, the mRNA level of Wnt3 was not changed after knockdown of EGFR (supplemental Figure 6) . 
Next, we pre-treated the SKBR3/100-8 with siRNA-EGFR, followed by treatment with 10μg/ml of trastuzumab. We found that down regulation of EGFR by siRNA-EGFR had no effect on cell invasiveness of SKBR3/100-8 cells, however, increased their response to trastuzumab induced inhibition of cell growth significantly ( Figure 4D ). The data suggests that the increase in EGFR in SKBR3/100-8 and BT474/100-2 leads to resistance to trastuzumab induced inhibition of cell growth, but may not be responsible for cell invasiveness directly. Since the SKBR3/100-8 showed increase in HER2/HER3 dimerization, similar experiments were performed on SKBR3/100-8 cells pre-treated with siRNA-HER3. An apparent reduction in invasion by HER3 knockdown did not achieve significance (supplemental Figure 7A) . However, the cell growth inhibition by trastuzumab was increased significantly after HER3 knockdown (supplemental Figure 7B) .
Thus, the data suggested that Wnt3 acted as a key mediator in the localization of β-catenin and controls EMT-like transition resulting in increase in cell invasion, proliferation, transactivation of EGFR. These events contribute to the increase in resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Overexpressing Wnt3 promotes EMT and reduces sensitivity to trastuzumab in SKBR3 wild type cells
To ascertain the role of Wnt3 in EMT-like transition and trastuzumab resistance, a full length Wnt3 gene was stably transfected into parental or wild type SKBR3 cells. Figure 5A shows that the Wnt3 transfectants, SKBR3/Wnt3-7 and SKBR3/Wnt3-9 clones, had significant increase in the mRNA levels of Wnt3 compared to the vector transfectant, SKBR3/pGFPV3 cells. The mRNA level of E-cadherin was down-regulated and N-cadherin was up-regulated in 
SKBR3/Wnt3-7 and SKBR3/Wnt3-9 compared with SKBR3/pGFPV3 ( Figure 5B ). SKBR3/Wnt3-7 and SKBR3/Wnt3-9 also had significant increase in Twist and SLUG ( Figure   5B ), but no changes in Vimentin ( Figure 5A ). Data in Figure 5C confirmed that the protein level of E-cadherin was down-regulated and N-cadherin was up-regulated following the up-regulation of Wnt3 protein in both SKBR3/Wnt3-7 and SKBR3/Wnt3-9 cells. The Twist protein level, however, was not changed in these two Wnt3 transfectants ( Figure 5C ). The increased Wnt3 expression reduced the growth -inhibiting effect of trastuzumab. Figure 5D shows that after 3 days of trastuzumab (20μg/ml to 200μg/ml) treatment, cell growth was inhibited by 32% to 42% in the parental line, SKBR3, and 30% to 40% in SKBR3/pGFP3. However, cells transfected with full length Wnt3 showed significantly decreased sensitivity to trastuzumab. The cell growth inhibition by 20μg/ml to 200μg/ml of trastuzumab was less than 10% in SKBR3/Wnt3-7 and SKBR3/Wnt3-9 ( Figure 5D ). This data confirmed the role of Wnt3 in EMT-like transition on the cells that developed resistance to trastuzumab.
Discussion
The resistance to therapy is one of the biggest challenges in breast cancer treatment. Despite the success of trastuzumab as a monotherapy agent, a significant portion of HER2-positive breast cancers respond poorly to the treatment (12, 13). The underlying mechanisms responsible for the resistance are still not clear.
The EGFR/HER2 cross-talk has been suggested as one of the mechanisms of the development of trastuzumab resistance in HER2-overexpressing breast cancer cells (14, 15 We performed microarray analysis to identify the specific signaling pathway that mediated genes involved in HER2-overexpressing breast cancer cells' resistance to trastuzumab. Twenty-two genes that are part of the Wnt pathway were either up or down-regulated two or more fold in SKBR3/100-8 cells compared to parental SKBR3 cells. In addition, a series of Wnt/β-catenin signaling molecules including β-catenin, c-Myc, c-Jun, Sox9, and survivin were up-regulated in both SKBR3/100-8 and BT474/100-2 cells.
Deregulation of the Wnt signaling pathway has been associated with the development and progression of several types of human cancers including colorectal cancer (CRC), prostate cancer, breast cancer and melanoma (11, (17) (18) (19) (20) (21) . In CRC, the activation of the Wnt/β-catenin pathway is mainly due to mutation or lost function of the APC gene or protein in a ligand independent manner (11) . The activation of the Wnt pathway in breast cancer, however, is more likely due to co-expression of Wnt ligands and FZD receptors (11, (22) (23) (24) (25) . The Wnt ligands, Wnt1, Wnt3a, Wnt4, Wnt5a, and Wnt7b have been reported to mediate cell proliferation and migration through canonical or noncanonical Wnt pathways in breast cancer (11, 16, 24, 25, 26) . 
